

DIVI'S LABORATORIES LIMITED

CIN No.L24110TG1990PLC011854

**1-72/23(P)/DIVIS/303, Cyber Hills, Gachibowli
Hyderabad – 500 032 Telangana, India**

Phone: 91-40-23786300 email: cs@divislabs.com

Press Release dated 6th November 2021

Divi's Labs earns a PAT of ₹ 606 crores for Q2 of FY22 on Consolidated Basis

Consolidated Results


Divi's Laboratories has earned a consolidated total income of ₹ 2007 crores for quarter ended 30th September 2021 as against a consolidated total income of ₹ 1763 crores in the corresponding quarter of the previous year.

Profit before Tax (PBT) for the quarter amounted to ₹ 760 crores as against a PBT of ₹ 693 crores for the corresponding quarter of the last year.

Profit after Tax (PAT) for the quarter grew by 17% to ₹ 606 crores as against a PAT of ₹ 520 crores for the corresponding quarter of the last year.

For the current quarter, we have a forex loss of ₹ 7 crores as against a loss of ₹ 16 crores during the corresponding quarter of last year.

For the half-year ended 30th September 2021, the company earned a consolidated total income of ₹ 3996 crores as against a consolidated total income of ₹ 3506 crores during the previous half-year. PAT for the current half-year came to ₹ 1164 crores as against ₹ 1012 crores for the previous half-year. For the current half-year, we had a forex gain of ₹ 13 crores as against a loss of ₹ 11 crores during the corresponding period last year.



Standalone Results

On a standalone basis, the company's earnings are as given below:

₹ in crores

Particulars	For the Quarter ended		For the half year ended	
	30-09-21	30-09-20	30-09-21	30-09-20
Total Income	1987	1727	3966	3450
PBT	760	685	1574	1346
PAT	606	513	1158	1006

Forex Gain/(loss)

Particulars of forex gain/(loss) for the period are given below:

₹ in crores

Particulars	For the Quarter ended		For the period ended	
	30-09-21	30-09-20	30-09-21	30-09-20
Forex gain/(loss)	(7)	(12)	12	(7)

The company continues to have near normal operations during the quarter complying to all Covid-19 protocols.